U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07189169) titled 'QA108 Phase III Study in Subjects With Intermediate AMD' on Sept. 14.
Brief Summary: This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.
Study Start Date: July 08
Study Type: INTERVENTIONAL
Condition:
Intermediate Age-Related Macular Degeneration
Intervention:
DRUG: QA108 granules
Take the medication as required for 24 weeks
DRUG: QA108 granules placebo
Take the medication as required for 24 weeks
Recruitment Status: RECRUITING
Sponsor: Smilebiotek Zhuhai Limited
Publ...